Skip to Content
Cancer Diagnosis Program (CDP) — Biorepositories & Biospecimen Research Branch (BBRB) Cancer Diagnosis Program (CDP) Biorepositories & Biospecimen Research Branch (BBRB)
Contact NExT
Show menu
Search this site
Last Updated: 08/20/18

Current Funding Opportunities

Visit this page often to find new biospecimen-related funding opportunities from the NCI Biorepositories and Biospecimen Research Branch and other NIH Research Programs.

Cancer Moonshot Biobank Project - Institutional Review Board (IRB)

In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., seeks a subcontractor to carry out the IRB review requirements as specified under the Health and Human Services (HHS) regulations at 45 Code of Federal Regulations (CFR) part 46. There are two main tasks required for this project: 1) to serve as a single IRB for up to 150 participating Biospecimen Source Sites (BSS), and 2) to serve as the IRB for the Biospecimen Core Resource (BCR). Proposal Due Date: Wednesday, September 5, 2018.

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)


Posted date: April 5, 2016; Expiration date: June 23, 2017
Application receipt dates: June 22, 2016; February 13, 2017; October 11, 2017; June 22, 2018, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to preanalytical variability in tissue biopsy biospecimens. The program will tie in with current efforts to optimize clinical biomarker assays utilized in NCI-sponsored clinical trials. Results from this research program will improve the understanding of how biopsy collection, processing, and storage procedures may affect assay detection limits for current and emerging clinical biomarkers, as well as expedite clinical biomarker assay development through the evidence-based standardization of biopsy handling practices.

The FOA will fund multidisciplinary teams that will constitute a collaborative network using a U01 Cooperative Agreement. Each team's application will focus on specific biomarker assays and associated questions in biospecimen science, and present a research plan for acquiring the needed biospecimens. Multidisciplinary scientific teams will be involved, including pathologists, oncologists, radiologists, molecular biologists, and statisticians, as the work requires expertise and perspectives in clinical medicine, knowledge of the unique issues related to obtaining biopsy biospecimens, biology and technology platforms, and experimental design and analysis. These teams must include investigators currently involved in NCI Phase I and Phase II clinical trials. Projects will involve defining workable biospecimen conditions for trials that utilize a particular type of biopsy (e.g. lung aspirates, liver biopsies) in a biomarker assay system (e.g. NGS for mutation-targeted drug trials; multi-analyte IHC/IFA or targeted mass spec for PD assays/pathway analysis) to detect emerging clinical biomarkers.

CDP contact: Dr. Abhi Rao, 240-276-5715,

Past Funding Opportunities

A complete list of past funding opportunities is available in the Past Funding Opportunities section.

Complementary Funding Opportunities

A list of complementary funding opportunities is available in the Complementary Funding Opportunities section.